Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Dynamis Therapeutics Inc.
DescriptionReceptor for advanced glycation end products (RAGE) inhibitor
Molecular Target Receptor for advanced glycation endproducts (RAGE)
Mechanism of ActionReceptor for advanced glycation endproducts (RAGE) antagonist
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationDiabetic retinopathy
Indication DetailsTreat diabetic retinopathy (DR)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today